CN107693576A - A kind of Chinese medicine composition for being used to treat coronary heart disease - Google Patents
A kind of Chinese medicine composition for being used to treat coronary heart disease Download PDFInfo
- Publication number
- CN107693576A CN107693576A CN201711210392.4A CN201711210392A CN107693576A CN 107693576 A CN107693576 A CN 107693576A CN 201711210392 A CN201711210392 A CN 201711210392A CN 107693576 A CN107693576 A CN 107693576A
- Authority
- CN
- China
- Prior art keywords
- weight
- ethanol
- total
- amount
- under reduced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Abstract
The invention discloses a kind of Chinese medicinal effective-part composition for treating coronary heart disease disease, belong to the field of Chinese medicines.Said composition from Radix Codonopsis by extracting Radix Codonopsis total starches, extracting from the Radix Astragali astragalus root total saponin, extract extraction melia toosendan seed total flavonoid in salvianolic acid and Fructus meliae toosendan from the red sage root and form according to a certain ratio, add pharmacy customary adjuvant, various formulations are made, can be clinically used for treating coronary heart disease disease.
Description
Technical field
The present invention relates to a kind of Chinese medicinal effective-part composition with treatment coronary heart disease disease effect and preparation method thereof,
Chinese medicinal effective-part composition specifically extracted from Radix Codonopsis, the Radix Astragali, the red sage root, Fructus meliae toosendan and preparation method thereof, in belonging to
Medicine field.
Background technology
Coronary heart disease is the abbreviation of coronary cardiopathy, is a kind of most common heart disease, refers to because coronary artery is narrow
Myocardial dysfunction or organic disease caused by narrow, blood supply insufficiency, therefore also known as ischemic cardiomyopathy.The generation of coronary heart disease with
The degree and number of coronary atherosclerosis have substantial connection, and coronary heart disease is one of global death rate highest disease,
According to the report of the World Health Organization, nineteen ninety is global and the China coronary death rate is respectively 131.3/10 ten thousand and 55.7/10
It is respectively 105.7/10 ten thousand and 70.1/10 ten thousand when ten thousand, 2010, global coronary heart disease death rate declines 20% between 20 years, in China
Rise 31.6%.The World Health Organization proposes the target for reducing by 25% global chronic disease premature death in 2025.Investigation display,
In Chinese premature death reason ranking, coronary heart disease rises to second, and Women with Coronary Heart Disease premature death situation by the 7th
It is even more serious.Beijing area investigation display in 2007~2015, the Incidence of CHD of different age group crowd are presented
The trend of liter, therefore young colony's coronary heart disease treatment situation allows of no optimist.
At present, western medical treatment coronary heart disease is mainly in terms of drug therapy or surgical operation therapy two.Drug therapy can be delayed
Symptom is solved, anginal breaking-out and myocardial infarction are reduced, mainly including nitrate esters medicine, calcium channel blocker, endothelium
Angiotensin system inhibitor and beta-Blocking agent etc., nitrate esters medicine are the routine administrations of Stable Angina Pectoris, but easily
Generation drug resistance, declines drug effectiveness；Second generation calcium channel blocker has slow release effect, can reduce side effect, prolong
Long duration, but the gastrointestinal function of patient may influence curative effect of medication；Renin-angiotensin system inhibitor includes
Angiotensin converting enzyme inhibitor, hypertensin 2 receptor antagonist and aldosterone antagonists.For acute myocardial infarction AMI
Or the patient that myocardial infarction merges cardiac insufficiency occurs in the recent period, such medicine should be especially used, but easily occur obvious dry
Cough side effect, hypertensin 2 receptor antagonist can be used instead, it is noted that preventing that blood pressure is relatively low during medication.Operative treatment can
With by place support with put up a bridge, but carry out stent procedure need blood vessel diameter to be more than 2.25mm, so using by certain
Limitation, bypass surgery can solve the problem once and for all, but need out chest, and patient bears huge wound, cause operation limited.
The traditional Chinese medical science thinks that coronary heart disease belongs to obstruction of qi in the chest category.Mainly due to worn with age, healthy tendency virtual loss, function is damaged,
Yin and yang qi and blood disorder, plus the influence of the factors such as inernal injuries caused by seven emotions, eating and drinking without temperance, cold stimulation, work and rest immoderation, cause stagnation of the circulation of vital energy blood
The stasis of blood, hypofunction of YANG QI in chest, the turbid interior life of phlegm, make heart vessel blockage stasis and cause a disease.Wherein, zang-fu differentiation qi and blood functional disturbance, human body yin and yang in equilibrium
Balance be destroyed, be morbidity immanent cause.Therefore coronary heart disease be one " asthenia in origin and asthenia in superficiality " card, the heart, liver, spleen, lung, kidney five
It is dirty it is deficient be disease this, including the deficiency of vital energy, the deficiency of Yin, the deficiency of yang and Yang Tuo；The stagnation of the circulation of vital energy, blood stasis, phlegm is turbid, it is cold it is solidifying be disease mark.This real void of mark
It is the pathogenic characteristic of coronary heart disease.Treating coronary disease with traditional Chinese medicine, focus on qi and activate blood circulation, resolving sputum, wash drink, treating a disease by looking into both its root cause and symptoms.Pass through QI invigorating
The stasis of blood, neovascularization growth can be promoted, improve myocardial ischemia, lipid-loweringing viscosity reduction, eliminate patch, and play antithrombus formation, the mistake of the anti-rhythm of the heart
Often, the effect of antiatherosclerosis, cardiovascular and cerebrovascular malignant event is avoided to occur.
But because prepared slices of Chinese crude drugs active constituent content is low, dose is big, it has not been convenient to, flavour of a drug are bitter, so being not easy by patient
Receive, but the extraction Jing Guo modern science technique so that active constituent content is improved, and dosage is reduced, convenient to take, and good medicine
It is no longer bitter to the taste, add the crowd of receiving.
The content of the invention
It is an object of the present invention to provide a kind of effective ingredient in Chinese combination with the disease effect for the treatment of coronary heart disease
Thing；
It is another object of the present invention to provide the preparation method of above-mentioned Chinese medicine composition and purposes.
The first object of the present invention：Using Radix Codonopsis total starches, astragalus root total saponin, salvianolic acid, melia toosendan seed total flavonoid as original
Material, proper pharmaceutical excipients are added, the formulation of correlation is made.
The composition and ratio of the bulk drug of the composition of medicine of the present invention are：The parts by weight of Radix Codonopsis total starches 10, the total soap of the Radix Astragali
The parts by weight of glycosides 8, the parts by weight of salvianolic acid 12, the parts by weight of melia toosendan seed total flavonoid 8.
Total starches are not less than the 60% of extract, in astragalus root total saponin active component in above-mentioned Radix Codonopsis total starches active component
The content of Astragaloside IV is 0.08%~0.112%, in salvianolic acid active component the content of tanshin polyphenolic acid B for 6%~
8.4%, the content of general flavone must not be less than the 50% of extract in Fructus meliae toosendan total flavone valid target.
The pharmaceutical composition can add corresponding auxiliary material, and any of tablet, granule, hard capsule is made.Then
Other, which can be added, has active component, active ingredient, the synthetic or semi-synthetic for the treatment of coronary heart disease disease medicament
Product, corresponding auxiliary material is then added, any of tablet, granule, hard capsule is made.
The preparation method of Chinese medicine composition of the present invention comprises the following steps：
The preparation of Radix Codonopsis total starches：Codonopsis pilosula is taken, 10 times of amount water of medicinal material weight is added and extracts 3 times, each 2h, filtration,
Filtrate merges, and is concentrated under reduced pressure into 1g crude drugs/mL, adds ethanol to alcohol content 50%, and refrigeration stands 12h, and filtration, filtrate is continued plus second
Alcohol collects precipitation, repeatedly purifying precipitation, adding 15 times to measure water makes fully to dissolve, and adds 4% tannic acid, mixes, quiet to alcohol content 80%
12h is put, is centrifuged, takes supernatant to add 2% activated carbon, is decolourized 3 times in 80 DEG C of insulations, 0.5h/ times, filtration, filtrate decompression concentration,
Dry, obtain Radix Codonopsis total starches；Wherein polyoses content is not less than the 60% of extract；
The preparation of astragalus root total saponin：Take Milkvetch Root, add medicinal material 8 times of weight alcohol reflux 2 times, 1.5 hours every time, mistake
Filter, filter residue repeats once, merges extract solution, filtrate is concentrated under reduced pressure on rotary evaporimeter, reclaims ethanol, to relative
Density is 1:1~1:1.5, with 1mL/min flow velocity by D101 macroreticular resins, 8BV is washed to neutrality, 10BV ethanol elutions,
Solvent is recovered under reduced pressure in eluant, eluent, dries, obtains astragalus root total saponin；Wherein the content of Astragaloside IV is 0.08%~0.112%；
The preparation of salvianolic acid：Red rooted salvia is taken, the 8 times of amount decoctings of medicinal material weight is added and boils 1.5 hours, after filtering, filter
Slag repeats once, merges filtrate twice, is concentrated into relative density as 1:1~1:1.3, let cool, add ethanol to alcohol content
Up to 60%, 12h is stood, filtration, reclaims ethanol, and is concentrated into relative density as 1：1.2, D101 is passed through with 1mL/min flow velocity
Macroreticular resin, applied sample amount are that the ratio of crude drug and dried resin is 1: 1, and macroporous resin column blade diameter length ratio is that 1: 6,6BV is washed to neutrality,
Solvent is recovered under reduced pressure in 8BV ethanol elutions, eluant, eluent, dries, obtains salvianolic acid；Wherein the content of tanshin polyphenolic acid B be 6%~
8.4%；
The preparation of melia toosendan seed total flavonoid：Fructus meliae toosendan medicinal material is taken, 6 times is added and measures petroleum ethers backflow degreasing 3 times, each 2h, take out
Filter, petroleum ether volatilize；Fructus meliae toosendan after degreasing, 15 times of 70% alcohol refluxs of amount are added to extract 2 times, each 1.5h, filtration, filtrate is closed
And ethanol is recovered under reduced pressure, concentrate is diluted with water, according to amount of resin:Medicinal material amount is 1:1 by macroporous resin column, first with 6 times of amounts
Deionized water elutes, then with 8 times of 70% ethanol elutions of amount, collects eluent, ethanol is recovered under reduced pressure and concentrates, dry, obtain melia toosendan
Seed total flavonoid；Wherein general flavone content is not less than the 50% of extract；
Weight proportion according to each active component takes above-mentioned four parts of active components, is not added with auxiliary material or addition pharmacy is routinely auxiliary
Material, is made pharmaceutically acceptable formulation.
The content assaying method of Radix Codonopsis total starches is：Precision weighs 105 DEG C of dryings to the glucose control product 10mg of constant weight,
It is placed in 100mL volumetric flasks, after adding distilled water dissolving completely, is settled to scale, shakes up, it is 100ug/mL to obtain concentration of glucose
Standard liquid.Respectively it is accurate inhale glucose standards solution 0.0mL, 0.2mL, 0.4mL, 0.6mL, 0.8mL, 1.0mL, 1.2mL,
1.4mL adds distilled water to mend to 2.0mL in 10mL tool plug test tubes, is separately added into 6% phenol solution 1.0mL mixings, rapidly joins
The 5.0mL concentrated sulfuric acids, mix, after 60 DEG C of insulation reaction 15min, stop reacting with ice-water bath 15min, using No. 0 pipe as reference,
Absorbance is surveyed at 490nm, using the amount of glucose as abscissa, absorbance is ordinate, draws standard curve.Take Radix Codonopsis total starches
Active component 15mg, it is placed in 100mL volumetric flasks, after adding distilled water dissolving completely, is settled to scale.Draw 1mL test solutions
In 10mL tool plug test tubes, add distilled water to mend to 2.0mL, be separately added into 6% phenol solution 1.0mL mixings, rapidly join 5.0mL
The concentrated sulfuric acid, mix, after 60 DEG C of insulation reaction 15min, stop reacting with ice-water bath 15min, determine absorbance, it is bent to substitute into standard
In line, calculate and produce.
Astragalus root total saponin content assaying method is：Precision weighs the Astragaloside IV through phosphorus pentoxide drying to constant weight
4.3mg, add methanol dissolving to be settled to 10mL, every milliliter of 0.43mg containing Astragaloside IV solution is made, produces.
Precision pipettes reference substance solution 0,0.1,0.2,0.3,0.4,0.5,0.6mL and is separately added into 7 dry tool plug test tubes
In, water-bath volatilizes solvent, each 50mL/L vanillic aldehydes glacial acetic acid solution 0.2mL, perchloric acid 0.8mL, in 60 for adding Fresh
DEG C water bath with thermostatic control heating 15min, takes out, and flowing water cooling 2min, acetic acid 5mL on the rocks, shakes up, reagent blank of accompanying, according to light splitting light
Degree method is tested, and trap is determined at 560nm wavelength.Using trap as ordinate, Astragaloside IV micrograms are abscissa, are drawn
Standard curve.Astragalus root total saponin active component 10mg is taken, adds methanol dissolving to be settled to 10mL.Need testing solution 0.5mL is taken, is put dry
In dry tool plug test tube, water-bath volatilizes solvent, each 50mL/L vanillic aldehyde glacial acetic acid solution 0.2mL for adding Fresh, perchloric acid
0.8mL, 15min is heated in 60 DEG C of waters bath with thermostatic control, is taken out, flowing water cooling 2min, acetic acid 5mL on the rocks, shaken up, determine absorbance,
Substitute into standard curve, calculate and produce.
Salvianolic acid content assaying method is：Precision weighs tanshin polyphenolic acid B reference substance 1.30mg and put in 2mL measuring bottles, adds water
Dissolve and be diluted to scale, shake up, as reference substance solution.Precision draws solution 0,0.1,0.2,0.3,0.4, the 0.5mL, point
Do not put in 5mL measuring bottles, be diluted with water to scale, shake up.Using water as blank, extinction is determined at ultraviolet specrophotometer 288nm
Angle value.Using sample size as abscissa, absorbance is ordinate, draws standard curve.Salvianolic acid active component 10mg is taken, is put
In 25mL volumetric flasks, scale is diluted with water to, is shaken up, using water as blank, absorbance is determined at ultraviolet specrophotometer 288nm
Value, substitute into standard curve, calculate and produce.
Fructus meliae toosendan Determination Method of Flavone Content：Precision weigh be dried under reduced pressure at 120 DEG C to constant weight control substance of Rutin about
10mg, put in 100mL volumetric flasks, add 70% ethanol 70mL, putting water-bath low-grade fever makes dissolving, lets cool, and adds 70% ethanol to be shaken to scale
It is even, produce.Precision draws reference substance solution 1.0,2.0,3.0,4.0,5.0mL, is respectively placed in 10mL measuring bottles, adds water respectively
4.0th, 3.0,2.0,1.0,0, add 5% sodium nitrite solution 0.3mL, shake up, place 6min, add 10% aluminum nitrate solution 0.3mL,
Shake up, place 6min, add 4% sodium hydroxide 4mL, add water scale, shake up, place 12min；Blank solution is obtained with legal system.In
Absorbance is determined at 510nm.Using trap as ordinate, concentration is abscissa, draws standard curve.Test sample 100mg is taken, extremely
In 100mL volumetric flasks, 70% ethanol is added to shake up, filter to scale.Precision measures filtrate 3mL, adds 2mL water, adds 5% nitrous acid
Sodium solution 0.3mL, shakes up, and places 6min, adds 10% aluminum nitrate solution 0.3mL, shake up, and places 6min, adds 4% sodium hydroxide
4mL, scale is added water, shaken up, place 12min.Absorbance is determined in 510nm, and content is calculated according to calibration curve equation.
After the contrast of inventor is preferred, it is determined that the best weight ratio of above-mentioned active component is：Radix Codonopsis total starches
10 parts by weight, the parts by weight of astragalus root total saponin 8, the parts by weight of salvianolic acid 12, the parts by weight of melia toosendan seed total flavonoid 8.Proportionally take
Above-mentioned Radix Codonopsis total starches, astragalus root total saponin, salvianolic acid and melia toosendan seed total flavonoid, are not added with auxiliary material or addition pharmacy is routinely auxiliary
Material, is made pharmaceutically acceptable formulation.
The formulation that pharmaceutical composition of the present invention can be made into is tablet, granule, hard capsule, soft capsule.
Foregoing pharmacy customary adjuvant includes but is not limited to adhesive, such as cellulose derivative, alginates, gelatin
And polyvinylpyrrolidone；Diluent, starch, Icing Sugar, dextrin, lactose, microcrystalline cellulose, mannitol；Lubricant, such as talcum
Powder, magnesium stearate, superfine silica gel powder and polyethylene glycol；Disintegrant, such as carboxyrnethyl starch sodium, low-substituted hydroxypropyl methylcellulose, crosslinking carboxylic
Methylcellulose；Sorbefacient, such as quaternary ammonium compound；Surfactant, such as lauryl sodium sulfate；Excipient, as lactose,
Starch, sucrose, dextrin, calcium carbonate, aluminum sulfate, magnesia, magnesium stearate, sodium acid carbonate, glycerine, propane diols, polyethylene glycol, mountain
Pears sugar alcohol, lanolin, vaseline, microcrystalline cellulose, honeybee are cured, wood is cured, atoleine, resin, advanced wax, pressure sensitive adhesive, semi-synthetic
Fatty acid ester etc..
Active component composition of the present invention is used to treat coronary heart disease disease.
Beneficial effect
The present invention, in combination with correlative study achievement both domestic and external, is preced with using Traditional Chinese medical theory as guiding theory in treatment
The aspect significant effect of worry.Using the red sage root as monarch drug in a prescription in side, red sage root bitter, it is slightly cold, the thoughts of returning home, Liver Channel.Effect is promoting blood circulation, clearly
Heart relieving restlessness, cool blood to disappear carbuncle.For the illnesss such as chest impediment and cardialgia, gastral cavity abdomen hypochondriac pain, the accumulation of lump in the abdomen lump in the abdomen, hot numbness pain, dysphoria and insomnia, modern times doctor
Think that root of red-rooted salvia phenolic acid constituents can reduce the scope of myocardial infarction, mitigates its state of an illness, while has obvious suppression blood platelet
Aggregation, anti-freezing, molten fine and reduction blood fat, antiatherosclerosis effect, therefore be monarch.The Radix Astragali is ministerial drug, and the Radix Astragali is sweet, tepor,
Return lung, spleen, liver and kidney channel, astragalus polyose have reduce blood viscosity, reduce thrombosis, reduce blood pressure, cardioprotection etc. is made
With, therefore be ministerial drug.Fructus meliae toosendan is adjutant, and Fructus meliae toosendan is bitter, cold, Return liver, small intestine, bladder warp, and flavones has anti-oxidant in Fructus meliae toosendan
Effect, the oxidative modification for suppressing low-density lipoprotein can be reduced and remove free radical, so that the generation of atherosclerosis,
It is final to reduce coronary heart disease odds, therefore be adjutant.For Radix Codonopsis to make medicine, Radix Codonopsis is sweet, mild-natured, returns spleen, lung channel, has bowl spares
The effect of QI invigorating and taste, can coordinating the drug actions of a prescription, priming guides drugs to illness station, and total starches can improve immunity in the Radix Astragali, protects the heart
It is dirty, therefore to make medicine.Each medicine complements each other in we, indispensable, by traditional Chinese medical science monarch, minister, helps, makes theoretical reasonable formula, plays altogether
Promoting blood circulation and removing blood stasis, yin-nourishing is promoted blood circulation, is warming heart yang, regulating qi and dredging collateral work(.
Product composition of the present invention is clear and definite, and curative effect is stable, and dose is small, safe, not only conforms with Chinese Traditional Medicine treatment
The principles of formulating prescriptions of coronary heart disease, and meet the demand for development of the modernization of Chinese medicine, to promoting medicinal industry from copying to autonomous innovation
Change and to promoting China's internationalization of tcm significant.Through consulting pertinent literature and patent, do not retrieve with the red sage root,
The Radix Astragali, Fructus meliae toosendan, the active component of Radix Codonopsis produce and process and are made the treatment that Suitable pharmaceutical preparations are used for coronary heart disease as raw material
Or the report of auxiliary treatment.
For the pharmacological action of the further checking present invention, animal pharmacodynamic experiment is carried out with capsule of the present invention.
Content of the test：Influence research to isolated rat coronary flow.
1 reagent, sample and animal
1.1 reagent
Yellow Jackets
1.2 test sample
Sample 1：(capsule of the present invention)
Capsule prepared by embodiment 1.
Sample 2：
Radix Codonopsis 160g, Radix Astragali 120g, root tuber of aromatic turmeric 60g, sweet wormwood fruit 60g are taken, adds 10 times of amount decoctings to boil 2 hours, filters, the dregs of a decoction are again
Add 8 times of amount decoctings to boil 1.5 hours, filter, merging filtrate, be concentrated under reduced pressure, be dried under reduced pressure, crush, add starch to 150g, load
No. 1 capsule, per the tolerant 0.3g of intragranular, capsule is made.
Sample 3：
Radix Codonopsis total starches 100g, astragalus root total saponin 40g, salvianolic acid 20g are taken, starch is added to 300g, loads No. 1 glue
Capsule, per the tolerant 0.3g of intragranular, capsule is made.
Sample 4：
Radix Codonopsis total starches 100g, salvianolic acid 20g are taken, adds starch to load No. 1 capsule, every intragranular is tolerant to 300g
0.3g, capsule is made.
Before administration, above-mentioned corresponding preparations are taken, it is finely ground, required drug concentration is configured to using pure water.
1.3 experimental animal
Wistar rats, male, body weight (280 ± 20g) are provided by Shandong Traditional Chinese Medicine University's experimental animal center.
2 experimental methods
Wistar rats are taken, 80 rats are randomly divided into 1 group of sample, 2 groups of sample, 3 groups of sample, 4 groups of sample and blank
Group, after yellow Jackets 30mg/kg anesthesia, take out heart and put in 4 DEG C of perfusates, after cardiac arrest, be made immediately
Blangendorff samples.After heart recovers steady, from 3min and administration before the collateral administration 0.2mL of perfusion tube, record administration
3min coronary blood flow and heart rate afterwards.
Influence (x ± s, n=10) of the sample of table 1 to isolated rat coronary flow
Four groups of result of the tests are substantially the ＞ samples 3 of 1 ＞ samples of sample 2, sample 4.Combination matching selected by explanation is optimal.
Embodiment
Carry out the technical scheme that the present invention is furture elucidated below by way of specific embodiment, but claimed by the present patent application
Content not only that.Dosage in actual production is not limited only to the drug dose in example, can use ton, kilogram, gram etc.
Measurement unit, but the consumption proportion of each material medicine is also in accordance with the bright technical scheme of we.
Embodiment 1：
Prescription：Radix Codonopsis total starches 100g, astragalus root total saponin 80g, salvianolic acid 120g, melia toosendan seed total flavonoid 80g
Preparation method：The preparation of Radix Codonopsis total starches：Codonopsis pilosula is taken, 10 times of amount water of medicinal material weight is added and extracts 3 times, each 2h,
Filtration, filtrate merge, and are concentrated under reduced pressure into 1g crude drugs/mL, add ethanol to alcohol content 50%, and refrigeration stands 12h, filtration, filtrate after
Continuous plus ethanol to alcohol content 80%, collection precipitates, repeatedly purifying precipitation, adds 15 times of amount water to make fully to dissolve, 4% tannic acid of addition,
Mix, stand 12h, centrifugation, take supernatant to add 2% activated carbon, decolourized 3 times in 80 DEG C of insulations, 0.5h/ times, filtration, filtrate subtracts
Pressure concentration, dries, obtains Radix Codonopsis total starches；Wherein polyoses content is not less than the 60% of extract；
The preparation of astragalus root total saponin：Take Milkvetch Root, add medicinal material 8 times of weight alcohol reflux 2 times, 1.5 hours every time, mistake
Filter, filter residue repeats once, merges extract solution, filtrate is concentrated under reduced pressure on rotary evaporimeter, reclaims ethanol, to relative
Density is 1:1~1:1.5, with 1mL/min flow velocity by D101 macroreticular resins, 8BV is washed to neutrality, 10BV ethanol elutions,
Solvent is recovered under reduced pressure in eluant, eluent, dries, obtains astragalus root total saponin；Wherein the content of Astragaloside IV is 0.08%~0.112%；
The preparation of salvianolic acid：Red rooted salvia is taken, the 8 times of amount decoctings of medicinal material weight is added and boils 1.5 hours, after filtering, filter
Slag repeats once, merges filtrate twice, is concentrated into relative density as 1:1~1:1.3, let cool, add ethanol to alcohol content
Up to 60%, 12h is stood, filtration, reclaims ethanol, and is concentrated into relative density as 1：1.2, D101 is passed through with 1mL/min flow velocity
Macroreticular resin, applied sample amount are that the ratio of crude drug and dried resin is 1: 1, and macroporous resin column blade diameter length ratio is that 1: 6,6BV is washed to neutrality,
Solvent is recovered under reduced pressure in 8BV ethanol elutions, eluant, eluent, dries, obtains salvianolic acid；Wherein the content of tanshin polyphenolic acid B be 6%~
8.4%；
The preparation of melia toosendan seed total flavonoid：Fructus meliae toosendan medicinal material is taken, adds the amount petroleum ether backflow degreasing 3 times of 6 times of medicinal material weight, often
Secondary 2h, is filtered, and petroleum ether volatilizes；Fructus meliae toosendan after degreasing, 15 times of dosing material weight, 70% alcohol refluxs of amount extraction 2 times, every time
1.5h, filtration, filtrate merge, ethanol are recovered under reduced pressure, is diluted with water concentrate, according to amount of resin:Medicinal material amount is 1:1 passes through macropore
Resin column, first with 6 times of amount deionized water elutions, then with 8 times of 70% ethanol elutions of amount, eluent is collected, ethanol is recovered under reduced pressure simultaneously
Concentration, dry, obtain melia toosendan seed total flavonoid；Wherein general flavone content is not less than the 50% of extract；
Above-mentioned each active component is taken, is crushed, mixing, starch is added to 600g, mixes, granulation, load capsule, be made 2000
Grain, is produced.
Embodiment 2：
Prescription：Radix Codonopsis total starches 100g, astragalus root total saponin 80g, salvianolic acid 120g, melia toosendan seed total flavonoid 80g；
Preparation method：The preparation of Radix Codonopsis total starches：Codonopsis pilosula is taken, 10 times of amount water of medicinal material weight is added and extracts 3 times, each 2h,
Filtration, filtrate merge, and are concentrated under reduced pressure into 1g crude drugs/mL, add ethanol to alcohol content 50%, and refrigeration stands 12h, filtration, filtrate after
Continuous plus ethanol to alcohol content 80%, collection precipitates, repeatedly purifying precipitation, adds 15 times of amount water to make fully to dissolve, 4% tannic acid of addition,
Mix, stand 12h, centrifugation, take supernatant to add 2% activated carbon, decolourized 3 times in 80 DEG C of insulations, 0.5h/ times, filtration, filtrate subtracts
Pressure concentration, dries, obtains Radix Codonopsis total starches；Wherein polyoses content is not less than the 60% of extract；
The preparation of astragalus root total saponin：Take Milkvetch Root, add medicinal material 8 times of weight alcohol reflux 2 times, 1.5 hours every time, mistake
Filter, filter residue repeats once, merges extract solution, filtrate is concentrated under reduced pressure on rotary evaporimeter, reclaims ethanol, to relative
Density is 1:1~1:1.5, with 1mL/min flow velocity by D101 macroreticular resins, 8BV is washed to neutrality, 10BV ethanol elutions,
Solvent is recovered under reduced pressure in eluant, eluent, dries, obtains astragalus root total saponin；Wherein the content of Astragaloside IV is 0.08%~0.112%；
The preparation of salvianolic acid：Red rooted salvia is taken, the 8 times of amount decoctings of medicinal material weight is added and boils 1.5 hours, after filtering, filter
Slag repeats once, merges filtrate twice, is concentrated into relative density as 1:1~1:1.3, let cool, add ethanol to alcohol content
Up to 60%, 12h is stood, filtration, reclaims ethanol, and is concentrated into relative density as 1：1.2, D101 is passed through with 1mL/min flow velocity
Macroreticular resin, applied sample amount are that the ratio of crude drug and dried resin is 1: 1, and macroporous resin column blade diameter length ratio is that 1: 6,6BV is washed to neutrality,
Solvent is recovered under reduced pressure in 8BV ethanol elutions, eluant, eluent, dries, obtains salvianolic acid；Wherein the content of tanshin polyphenolic acid B be 6%~
8.4%；
The preparation of melia toosendan seed total flavonoid：Fructus meliae toosendan medicinal material is taken, 6 times is added and measures petroleum ethers backflow degreasing 3 times, each 2h, take out
Filter, petroleum ether volatilize；Fructus meliae toosendan after degreasing, 15 times of 70% alcohol refluxs of amount are added to extract 2 times, each 1.5h, filtration, filtrate is closed
And ethanol is recovered under reduced pressure, concentrate is diluted with water, according to amount of resin:Medicinal material amount is 1:1 by macroporous resin column, first with 6 times of amounts
Deionized water elutes, then with 8 times of 70% ethanol elutions of amount, collects eluent, ethanol is recovered under reduced pressure and concentrates, dry, obtain melia toosendan
Seed total flavonoid；Wherein general flavone content is not less than the 50% of extract；
Above-mentioned each active component is taken, is crushed, mixing, adds hydroxypropyl methylcellulose 120g, microcrystalline cellulose 90g, micro mist silicon
Glue 10g adds lactose to be mixed, granulation is tabletted, is made 2000, produces to 600g again.
Embodiment 3：
Prescription：Radix Codonopsis total starches 100g, astragalus root total saponin 80g, salvianolic acid 120g, melia toosendan seed total flavonoid 80g；
Preparation method：The preparation of Radix Codonopsis total starches：Codonopsis pilosula is taken, 10 times of amount water of medicinal material weight is added and extracts 3 times, each 2h,
Filtration, filtrate merge, and are concentrated under reduced pressure into 1g crude drugs/mL, add ethanol to alcohol content 50%, and refrigeration stands 12h, filtration, filtrate after
Continuous plus ethanol to alcohol content 80%, collection precipitates, repeatedly purifying precipitation, adds 15 times of amount water to make fully to dissolve, 4% tannic acid of addition,
Mix, stand 12h, centrifugation, take supernatant to add 2% activated carbon, decolourized 3 times in 80 DEG C of insulations, 0.5h/ times, filtration, filtrate subtracts
Pressure concentration, dries, obtains Radix Codonopsis total starches；Wherein polyoses content is not less than the 60% of extract；
The preparation of astragalus root total saponin：Take Milkvetch Root, add medicinal material 8 times of weight alcohol reflux 2 times, 1.5 hours every time, mistake
Filter, filter residue repeats once, merges extract solution, filtrate is concentrated under reduced pressure on rotary evaporimeter, reclaims ethanol, to relative
Density is 1:1~1:1.5, with 1mL/min flow velocity by D101 macroreticular resins, 8BV is washed to neutrality, 10BV ethanol elutions,
Solvent is recovered under reduced pressure in eluant, eluent, dries, obtains astragalus root total saponin；Wherein the content of Astragaloside IV is 0.08%~0.112%；
The preparation of salvianolic acid：Red rooted salvia is taken, the 8 times of amount decoctings of medicinal material weight is added and boils 1.5 hours, after filtering, filter
Slag repeats once, merges filtrate twice, is concentrated into relative density as 1:1~1:1.3, let cool, add ethanol to alcohol content
Up to 60%, 12h is stood, filtration, reclaims ethanol, and is concentrated into relative density as 1：1.2, D101 is passed through with 1mL/min flow velocity
Macroreticular resin, applied sample amount are that the ratio of crude drug and dried resin is 1: 1, and macroporous resin column blade diameter length ratio is that 1: 6,6BV is washed to neutrality,
Solvent is recovered under reduced pressure in 8BV ethanol elutions, eluant, eluent, dries, obtains salvianolic acid；Wherein the content of tanshin polyphenolic acid B be 6%~
8.4%；
The preparation of melia toosendan seed total flavonoid：Fructus meliae toosendan medicinal material is taken, 6 times is added and measures petroleum ethers backflow degreasing 3 times, each 2h, take out
Filter, petroleum ether volatilize；Fructus meliae toosendan after degreasing, 15 times of 70% alcohol refluxs of amount are added to extract 2 times, each 1.5h, filtration, filtrate is closed
And ethanol is recovered under reduced pressure, concentrate is diluted with water, according to amount of resin:Medicinal material amount is 1:1 by macroporous resin column, first with 6 times of amounts
Deionized water elutes, then with 8 times of 70% ethanol elutions of amount, collects eluent, ethanol is recovered under reduced pressure and concentrates, dry, obtain melia toosendan
Seed total flavonoid；
Above-mentioned each active component is taken, adds 8% starch, 90% alcohol granulation, produces.
Embodiment 4：
Prescription：Radix Codonopsis total starches 100g, astragalus root total saponin 80g, salvianolic acid 120g, melia toosendan seed total flavonoid 80g；
Preparation method：Radix Codonopsis total starches, astragalus root total saponin, salvianolic acid, melia toosendan seed total flavonoid addition polymerization ethylene glycol 400 are taken to total
500g is measured, is mixed, soft capsule is suppressed, is made 1000, produces.
Embodiment 5：Prescription：Radix Codonopsis total starches 100g, astragalus root total saponin 80g, salvianolic acid 120g, melia toosendan seed total flavonoid
80g；
Preparation method：Macrogol 4000 150g and Macrogol 6000 50g respectively, melting, add Radix Codonopsis total starches, the Radix Astragali
Total saposins, salvianolic acid, melia toosendan seed total flavonoid, mix, instill in tetramethyl silicone oil, dripping pill is made, produces.
Embodiment 6：Prescription：Radix Codonopsis total starches 10kg, astragalus root total saponin 8kg, salvianolic acid 12kg, melia toosendan seed total flavonoid
8kg；
Preparation method：Above-mentioned each active component is taken, adds 8% starch, 90% alcohol granulation, produces.
Embodiment 7：120 patients with coronary heart disease of made Granules in Treating of Example 6.Therapeutic scheme：Orally, once a bag,
3 times a day, 4 weeks are a course for the treatment of.As a result：55 are cured, is taken a turn for the better 33, effective 23, no effect 9, total effective rate is
92.5%.
Claims (4)
1. a kind of Chinese medicinal effective-part composition for being used to treat coronary heart disease, it is characterised in that be total by extracting Radix Codonopsis from Radix Codonopsis
Polysaccharide, astragalus root total saponin is extracted from the Radix Astragali, is extracted from the red sage root and melia toosendan seed total flavonoid is extracted in salvianolic acid and Fructus meliae toosendan
Composition, wherein, the weight proportion of each active component is：
The parts by weight of Radix Codonopsis total starches 9~30
The parts by weight of astragalus root total saponin 3~30
The parts by weight of salvianolic acid 10~15
The parts by weight of melia toosendan seed total flavonoid 5~10.
2. Chinese medicinal effective-part composition as claimed in claim 1, it is characterised in that the weight proportion of each active component is：Party
Join the parts by weight of total starches 10, the parts by weight of astragalus root total saponin 8, the parts by weight of salvianolic acid 12, the parts by weight of melia toosendan seed total flavonoid 8.
3. Chinese medicinal effective-part composition as claimed in claim 1 or 2, it is characterised in that its preparation method includes following step
Suddenly：
1. the preparation of Radix Codonopsis total starches：Codonopsis pilosula is taken, 8~20 times of amount water of medicinal material weight is added and extracts 1~3 time, each 2h,
Filtration, filtrate merge, and are concentrated under reduced pressure into 1g crude drugs/mL, and adding ethanol, refrigeration stands 12h, filtration to alcohol content 50%, and filtrate is continued
Ethanol is added to collect precipitation to alcohol content 80%, repeatedly purifying precipitation, add 5~20 times of amount water to make fully to dissolve, add 0.5%~5%
Tannic acid, mix, stand 12h, centrifugation, take supernatant to add 0.5%~5% activated carbon, decolourized 3 times in 80 DEG C of insulations, 0.5h/ times,
Filtration, filtrate decompression concentration, dries, obtains Radix Codonopsis total starches；Wherein polyoses content is not less than the 60% of extract；
2. the preparation of astragalus root total saponin：Take Milkvetch Root, add medicinal material 6~10 times of weight alcohol reflux 1~3 time, every time 1.5
Hour, filtering, filter residue repeats once, merges extract solution, filtrate is concentrated under reduced pressure on rotary evaporimeter, reclaims second
Alcohol, it is 1 to relative density:1~1:1.5, with 0.8~1mL/min flow velocity by D101 macroreticular resins, during 6~8BV is washed to
Property, solvent is recovered under reduced pressure in 8~10BV ethanol elutions, eluant, eluent, dry, obtains astragalus root total saponin；The content of wherein Astragaloside IV is
0.08%~0.112%；
3. the preparation of salvianolic acid：Red rooted salvia is taken, 6~8 times of amount decoctings of medicinal material weight is added and boils 1 hour, after filtering, filter
Slag repeats once, merges filtrate twice, is concentrated into relative density as 1:1~1:1.3, let cool, add ethanol to alcohol content
Up to 60%, 12 h are stood, filtration, reclaim ethanol, and are concentrated into relative density as 1：1.3, led to 0.8~1mL/min flow velocity
Cross D101 macroreticular resins, applied sample amount is that the ratio of crude drug and dried resin is 1: 1, and macroporous resin column blade diameter length ratio is 1: 6,6~8BV washings
To neutrality, 8~10BV ethanol elutions, solvent is recovered under reduced pressure in eluant, eluent, dries, obtains salvianolic acid；Wherein tanshin polyphenolic acid B
Content is 6%~8.4%；
4. the preparation of melia toosendan seed total flavonoid：Fructus meliae toosendan medicinal material is taken, 6~10 times is added and measures petroleum ethers backflow degreasing 1~3 time, every time
2h, is filtered, and petroleum ether volatilizes；Fructus meliae toosendan after degreasing, 8~15 times are added to measure 60%~80% alcohol refluxs extraction 2 times, every time
1.5h, filtration, filtrate merge, ethanol are recovered under reduced pressure, is diluted with water concentrate, according to amount of resin:Medicinal material amount is 1:1 passes through macropore
Resin column, first with 6~8 times of amount deionized water elutions, then with 8~10 times of 70% ethanol elutions of amount, eluent is collected, is recovered under reduced pressure
Ethanol simultaneously concentrates, and dries, obtains melia toosendan seed total flavonoid；Wherein general flavone content must not be less than the 50% of extract；
Weight proportion according to each active component takes above-mentioned four parts of active components, it is characterised in that is added without or adds and pharmaceutically may be used
The auxiliary material of receiving, pill, tablet, granule, hard capsule, mixture, pill, soft capsule, effervescent tablet, injection is made
Or any of powder-injection.
4. the Chinese medicinal effective-part composition described in claim 1 or 2 is preparing the application in being used to treat medicaments for coronary disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711210392.4A CN107693576A (en) | 2017-11-28 | 2017-11-28 | A kind of Chinese medicine composition for being used to treat coronary heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711210392.4A CN107693576A (en) | 2017-11-28 | 2017-11-28 | A kind of Chinese medicine composition for being used to treat coronary heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107693576A true CN107693576A (en) | 2018-02-16 |
Family
ID=61181130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711210392.4A Withdrawn CN107693576A (en) | 2017-11-28 | 2017-11-28 | A kind of Chinese medicine composition for being used to treat coronary heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107693576A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115813989A (en) * | 2022-11-22 | 2023-03-21 | 烟台新时代健康产业有限公司 | Traditional Chinese medicine effective part composition for treating asthma and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1283482A (en) * | 2000-06-09 | 2001-02-14 | 安徽天洋药业有限公司 | Medicinal composition for treating cardiovascular disease and its preparing process |
| CN1981849A (en) * | 2005-12-16 | 2007-06-20 | 北京联合伟华药业有限公司 | Production and use for milkvetch root Shengmai injection |
-
2017
- 2017-11-28 CN CN201711210392.4A patent/CN107693576A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1283482A (en) * | 2000-06-09 | 2001-02-14 | 安徽天洋药业有限公司 | Medicinal composition for treating cardiovascular disease and its preparing process |
| CN1981849A (en) * | 2005-12-16 | 2007-06-20 | 北京联合伟华药业有限公司 | Production and use for milkvetch root Shengmai injection |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115813989A (en) * | 2022-11-22 | 2023-03-21 | 烟台新时代健康产业有限公司 | Traditional Chinese medicine effective part composition for treating asthma and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005051404A1 (en) | Pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases | |
| CN102120020B (en) | Medicinal composition for treating hyperplastic diseases of breast and hysteromyoma and preparation method thereof | |
| CN106474170B (en) | A kind of acanthopanax combination, preparation and its detection method | |
| CN105343232A (en) | Composition of effective parts of ground beetle small peptides for treating cardiovascular diseases | |
| CN102048841B (en) | Lactogenic traditional Chinese medicine composition and preparation method thereof | |
| CN100509009C (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof | |
| CN107693576A (en) | A kind of Chinese medicine composition for being used to treat coronary heart disease | |
| CN108452009A (en) | A kind of application including Common Leafflower Herb, rainbow conk, Radix Salviae Miltiorrhizae and the Chinese medicine composition of Asian puccoon in the drug for preparing treatment liver cancer | |
| CN101564466A (en) | Traditional Chinese medicine effective part composition containing antineoplastic active ingredients as well as preparation method and application thereof | |
| CN100509010C (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and making method thereof | |
| CN101152233B (en) | Pharmaceutical composition of snakegourd fruit and folium ginkgo | |
| CN1931233B (en) | Medicine composition of red sage and epimedium for treating cardiac and cerebral vascular diseases | |
| JP2007504099A (en) | Treatment of aspirin resistance using Tansan, its extract and composition | |
| CN102048890A (en) | Traditional Chinese medicine composition with galactagogue effect and preparation method thereof | |
| CN100427066C (en) | Pharmaceutical preparation with functions of clearing heat, removing dampness and benefiting gallbladder | |
| CN103446280A (en) | Combined medicine of pseudo-ginseng extract, ligusticum wallichii extract, safflower carthamus extract, radix puerariae extract and hawthorn extract as well as preparation and application of combined medicine | |
| CN102988779A (en) | Chinese medicine composition for treating hypertensive nephropathy and preparation method and application of Chinese medicine composition | |
| CN103784683B (en) | A kind of Chinese medicine composition treating obesity and its preparation method and application | |
| CN102824441B (en) | Method for preparing Fructus Aurantii ingredients having anti-liquid-accumulation activity, and use | |
| CN105664131A (en) | Hirudo small peptide effective part composition used for treating cardiovascular disease | |
| CN101176769B (en) | Pharmaceutical composition of cattail pollen and red orpin | |
| CN104116753A (en) | Application of aucubin to preparation of medicines for treating idiopathic pulmonary fibrosis | |
| CN104069312B (en) | Treat Chinese medicine composition of apoplexy and preparation method thereof, pharmaceutical preparation and application | |
| CN113633712B (en) | Traditional Chinese medicine composition for treating gout and oral preparation based on traditional Chinese medicine composition | |
| CN103908619B (en) | A kind of Chinese medicine gastrointestinal tomach-solvable type and intestinn-solvable type concentrated pill with functions of reinforcing spleen and benefiting intestine and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180216 |
|
| WW01 | Invention patent application withdrawn after publication |